RVMD ▲ +0.4% - Revolution Medicines, Inc.
$RVMD - Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
05-OCT-2026 08:00 AM ET
Share this post
More filings for $RVMD
RVMD ▼ -0.6% - Revolution Medicines, Inc.Sep 15, 2026RVMD ▼ -1.5% - Revolution Medicines, Inc.Sep 14, 2026RVMD ▲ +1.0% - Revolution Medicines, Inc.Sep 10, 2026RVMD ▼ -0.3% - Revolution Medicines, Inc.Sep 2, 2026RVMD ▲ +3.3% - Revolution Medicines, Inc.Aug 27, 2026RVMD - Revolution Medicines, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026
View full $RVMD filing history →💬 Comments
Loading comments…
Leave a comment